VI Partners, established in 2001, is a Swiss venture capital firm headquartered in Altendorf. It specializes in investing in early-stage and growth-phase companies within the healthcare, technology, biotechnology, and software sectors. The firm provides not only capital but also coaching and network support to promising start-ups, including university spin-offs. VI Partners has been advising multiple funds since its inception, with its first fund established in collaboration with McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ).
Buynomics GmbH, founded in 2018 and based in Cologne, Germany, specializes in developing and distributing pricing machine software and innovative AI solutions. The company creates Virtual Customers that simulate the buying behavior of real consumers, allowing businesses in the consumer-packaged goods and telecommunications sectors to gain accurate insights into customer preferences. By leveraging big data analytics and computer simulations, Buynomics enables its clients to make informed decisions regarding pricing, promotions, product offerings, and trade terms. This holistic approach links critical revenue levers and provides actionable recommendations, facilitating data-driven commercial strategies that promote profitability and sustainability.
Unique
Series A in 2025
Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.
Kadoa
Seed Round in 2025
Kadoa is an AI-powered no-code platform that allows anyone to build complex data workflows effortlessly.
Oplit
Seed Round in 2024
Oplit is a production planning platform that offers a comprehensive software solution aimed at enhancing profitability for industrial operations. The platform employs big data and artificial intelligence to optimize production planning by simulating and comparing various production strategies. It enables real-time monitoring of operations, facilitating collaboration among different departments such as production, logistics, and purchasing. By centralizing and visualizing critical information, Oplit allows manufacturers to make informed decisions and streamline their production processes, ultimately improving operational efficiency and effectiveness.
Somagenetix
Series A in 2024
Somagenetix is a biotechnology company focused on developing innovative gene therapies for phagocyte-related illnesses, particularly targeting severe inherited immune diseases, immunodeficiency, neurodegeneration, and cancer with brain metastases. The company specializes in discovering and developing stem cells from bone marrow and utilizing lentiviral vectors to deliver therapeutic genes. This approach aims to correct the underlying genetic defects in patients by transplanting gene-corrected cells back into the body, ultimately providing a potential cure for various monogenic disorders. With a commitment to advancing the field of gene therapy, Somagenetix aims to lead in creating first-in-class treatments that address significant medical needs.
Almer
Seed Round in 2024
Almer Technologies is a startup focused on creating compact and lightweight augmented reality (AR) glasses aimed at enhancing communication for frontline workers in industrial settings. The company offers a comprehensive AR solution that includes both hardware and software, partnering with industry leaders to integrate advanced functionalities. By equipping frontline workers with these AR glasses, Almer enables them to access expertise directly in their field of view, facilitating remote problem-solving and minimizing downtime. This innovative approach streamlines communication and improves operational efficiency in technical industries.
Flowit
Seed Round in 2024
Flowit provides an end-to-end approach that makes modern, digital HR a breeze allowing organizations to streamline their processes.
XO Life
Venture Round in 2024
XO Life operates an online platform focused on digital patient monitoring and engagement. The platform is designed to enhance patient education and support by offering real-world insights into patient preferences and treatment outcomes. It facilitates communication between patients and pharmaceutical companies, allowing for the exchange of feedback and information that improves adherence to treatments. By providing services such as patient companionship and insights into various drugs and diseases, XO Life aims to foster better relationships between patients and healthcare providers, ultimately contributing to improved patient outcomes and loyalty.
iOnctura
Series B in 2024
iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.
Unique
Seed Round in 2023
Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.
LeaseTeq
Series A in 2023
LeaseTeq is a FinTech company focused on transforming the automotive leasing experience through innovative digital solutions. Established in 2021, it aims to simplify the leasing process by offering a streamlined platform that enables both individuals and businesses to lease vehicles efficiently. The company's services prioritize convenience and speed, featuring a paperless application process that enhances environmental sustainability while ensuring discretion and security for users. Through its technology-driven approach, LeaseTeq seeks to make leasing more accessible and user-friendly.
Xeltis
Series D in 2023
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
Oculis Holding
Post in 2023
Oculis is a global biopharmaceutical company focused on advancing eye care and preserving vision through innovative drug delivery solutions. The company's unique platform enables effective drug absorption in both the anterior and posterior segments of the eye, allowing for the treatment of conditions such as diabetic macular edema (DME) with a simple topical application, thus eliminating the need for invasive procedures. Oculis is developing several therapeutic candidates, including OCS-01, a topical treatment for DME; OCS-02, aimed at addressing dry eye disease; and OCS-05, which targets acute optic neuritis and other neuro-ophthalmic disorders. This novel approach not only facilitates treatment for posterior eye diseases but also reduces the required frequency of applications for anterior conditions compared to traditional eye drops.
Acodis
Series A in 2023
Acodis is a developer of document digitalization software that transforms various types of documents into structured data quickly and efficiently. Utilizing artificial intelligence, Acodis' machine learning engine can read and comprehend documents similarly to humans, allowing businesses to automate data extraction across multiple formats and layouts. This capability significantly reduces the time and effort spent on manual data entry, enhances accuracy, and improves overall productivity. The software supports documents in any language and integrates seamlessly with existing systems, enabling users to export data via API to enhance their ERP, CRM, or RPA systems. By streamlining document processing, Acodis empowers organizations to derive valuable insights and optimize their business operations.
Vara
Series A in 2022
Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.
Araris Biotech
Series A in 2022
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
Sibylla Biotech
Series A in 2022
Sibylla Biotech S.R.L. is an Italian company focused on advancing rational drug design in the pharmaceutical sector. The company specializes in the research, development, and production of innovative therapeutic solutions, particularly through the creation of small molecule folding interfering degraders (FIDs) that target a variety of therapeutic areas. Additionally, Sibylla Biotech provides consultancy services in biotechnology and drug development. The company utilizes patent-based software that applies advanced algorithms and drug design protocols, enabling efficient drug discovery by optimizing reaction paths and streamlining data processes. This approach aims to enhance the rationalization of drug discovery efforts, ultimately contributing to the treatment of challenging medical conditions.
Ledgy
Series B in 2022
Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.
Skribble
Series A in 2022
Skribble is a Zurich-based platform that specializes in electronic signatures, enabling users to sign contracts digitally while ensuring that these signatures carry the same legal weight as handwritten ones under Swiss and EU law. Founded in 2018, Skribble provides a user-friendly interface that allows individuals and businesses to sign documents with a few clicks, streamlining the process of contract management. The platform incorporates signature management systems that facilitate the identification of signers, ensuring compliance with legal requirements. Through its services, Skribble aims to simplify the process of creating legally binding agreements in a digital format.
Morgen
Pre Seed Round in 2022
Morgen is a time management platform that simplifies the scheduling process by integrating multiple calendars and task management tools into a single application. As the complexity of time management increases, Morgen addresses this challenge by offering a holistic solution that allows users to plan, organize, and optimize their schedules effectively. The platform combines various calendar systems and communication channels, enabling users to manage all events, tasks, lists, and reminders in one place. With its native scheduling tool, Morgen helps individuals and teams reduce meeting chaos and streamline their daily activities, making time management more efficient and less fragmented.
Ninox
Venture Round in 2022
Ninox Software GmbH, based in Berlin, Germany, specializes in developing no-code business applications that empower teams to automate backoffice workflows without requiring programming expertise. The platform offers a variety of templates for functions such as customer relationship management, invoicing, project planning, and data synchronization, enabling over 2,800 companies across diverse industries to digitize their business processes efficiently. Ninox distinguishes itself in the rapidly growing market for no- and low-code application platforms by providing an intuitive onboarding experience akin to modern productivity apps while maintaining the flexibility of application creation. This approach facilitates broader adoption of its tools, allowing users to build fully-functional databases and improve productivity significantly.
Picterra
Series A in 2022
Picterra SA is a company that operates an online platform designed to create and automate artificial intelligence (AI) workflows for object detection in geospatial data. Founded in 2016 and headquartered in Écublens, Switzerland, Picterra combines AI with satellite, drone, and aerial imagery to provide optimized geo-information. This platform enables users to monitor and anticipate changes in their environments, delivering valuable insights across various industries, including aerial imaging, mapping, financial services, insurance, journalism, precision agriculture, real estate, utilities, infrastructure, and the public sector. By leveraging cloud-based machine learning capabilities, Picterra empowers clients to efficiently extract and analyze earth observation data, facilitating informed decision-making.
Unique
Seed Round in 2022
Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.
Altoida
Series A in 2022
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Acodis
Convertible Note in 2021
Acodis is a developer of document digitalization software that transforms various types of documents into structured data quickly and efficiently. Utilizing artificial intelligence, Acodis' machine learning engine can read and comprehend documents similarly to humans, allowing businesses to automate data extraction across multiple formats and layouts. This capability significantly reduces the time and effort spent on manual data entry, enhances accuracy, and improves overall productivity. The software supports documents in any language and integrates seamlessly with existing systems, enabling users to export data via API to enhance their ERP, CRM, or RPA systems. By streamlining document processing, Acodis empowers organizations to derive valuable insights and optimize their business operations.
Ledgy
Series A in 2021
Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.
Oculis Holding
Series C in 2021
Oculis is a global biopharmaceutical company focused on advancing eye care and preserving vision through innovative drug delivery solutions. The company's unique platform enables effective drug absorption in both the anterior and posterior segments of the eye, allowing for the treatment of conditions such as diabetic macular edema (DME) with a simple topical application, thus eliminating the need for invasive procedures. Oculis is developing several therapeutic candidates, including OCS-01, a topical treatment for DME; OCS-02, aimed at addressing dry eye disease; and OCS-05, which targets acute optic neuritis and other neuro-ophthalmic disorders. This novel approach not only facilitates treatment for posterior eye diseases but also reduces the required frequency of applications for anterior conditions compared to traditional eye drops.
CeQur Simplicity
Series C in 2021
CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.
MedLumics
Venture Round in 2021
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.
HighLife
Series C in 2020
HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.
Araris Biotech
Seed Round in 2020
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
iOnctura
Series A in 2020
iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.
JenaValve Technology
Series D in 2020
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
iOnctura
Series A in 2020
iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.
Araris Biotech
Seed Round in 2019
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
Smart Valor
Venture Round in 2019
Smart Valor AG is a blockchain-based fintech company based in Zug, Switzerland, established in 2017. It provides a comprehensive digital asset platform that facilitates the issuance and distribution of investment solutions and banking services. The company operates a digital asset exchange and offers asset management services, making it the first full-service digital asset provider in Switzerland and Liechtenstein. Smart Valor connects banks and fintechs to a decentralized network of investors, enabling access to tokenized and liquid investments across various asset classes, including real estate, currencies, and art. Additionally, it offers a white-label software-as-a-service solution that supports financial institutions with tools for compliance, performance tracking, and customer verification. The company has received recognition for its innovative approach, including an award from the Swiss governmental innovation agency Innosuisse.
Gamaya
Series B in 2019
Gamaya is a company focused on enhancing the efficiency and sustainability of both large-scale and small-holder farming through advanced farmland mapping and diagnostics solutions. It employs patented hyperspectral imaging technology, embedded cameras, and analytical software to convert raw hyperspectral and satellite data into actionable insights for farmers. This innovative approach enables farmers to optimize their use of water, fertilizers, chemicals, and fuel, ultimately improving the quality and quantity of their agricultural production. By facilitating better decision-making, Gamaya's solutions contribute to increased crop yields while minimizing environmental impact, thereby supporting sustainable agriculture and global food security.
Altoida
Series A in 2019
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Athelas
Series A in 2019
Athelas, Inc. is a healthcare company based in Mountain View, California, that specializes in developing and manufacturing in-home blood analysis devices aimed at diagnosing infections, inflammations, and malignancies. Founded in 2002, Athelas has created a portable optical unit that analyzes blood samples from a single drop, providing diagnostic reports to monitor the immune system. The company's FDA-cleared device is designed to help chronically ill patients manage their health at home, offering additional monitoring for blood pressure, weight, glucose levels, and medication adherence. This technology enables patients to monitor their immunity and assists healthcare providers in the early detection of conditions such as leukemia and other inflammatory diseases. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.
MESA Imaging
Series A in 2019
MESA Imaging specializes in the development and production of 3D time-of-flight cameras designed to capture full 3D images at video frame rates. The company utilizes the Time-of-Flight (TOF) principle and incorporates innovative technologies such as silo pixel architecture and the SR4000 sensor chip, which enhance distance measurement capabilities. MESA Imaging supplies its advanced camera systems to various industries, including video gaming, machine vision, automotive, and robotics, thereby contributing to the enhancement of image-related applications.
Ledgy
Seed Round in 2018
Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.
Amal Therapeutics
Series B in 2018
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Altoida
Convertible Note in 2018
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Xeltis
Series C in 2017
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
Amal Therapeutics
Series B in 2017
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Picodrill
Series A in 2017
PicoDRILL SA is a private company based in Lausanne, Switzerland, specializing in micromachining techniques for creating hole structures in glass and dielectric materials. The company has developed a proprietary process known as Electrothermal Self-focusing, which enables the controlled heating and evaporation of precisely defined volumes in various substrates, including glass, ceramics, silica, and sapphire. This innovative technology addresses drilling needs within the nanotechnology sector, providing advanced solutions for its partners and customers.
Lambda Health System
Seed Round in 2017
Lambda Health System SA specializes in the development and commercialization of innovative rehabilitation technology, particularly focusing on a robotic device known as the Lambda Robot. This device is designed to assist patients with locomotor disabilities, facilitating rehabilitation across various fields including neurorehabilitation, orthopedics, and geriatrics. The Lambda Robot allows therapists to perform exercises without the need for patient transfers between different machines, streamlining the rehabilitation process. Additionally, the company offers the Lambda Control Center, a platform that enables physicians to tailor exercises to individual patient needs while monitoring their progress and adjusting training parameters as necessary. The control center also incorporates engaging games and virtual reality applications aimed at addressing cognitive disorders. Founded in 2015 and based in Yverdon-Les-Bains, Switzerland, Lambda Health System emerged as a spin-off from the University of Applied Sciences of Canton de Vaud, focusing on creating cost-effective and user-friendly rehabilitation solutions.
Advanon
Series A in 2017
Advanon AG is an online financial services platform based in Zurich, Switzerland, focused on connecting small and medium-sized enterprises (SMEs) with investors. Established in 2015, the platform specializes in invoice financing, allowing SMEs to pre-finance their outstanding invoices. This service enables businesses to access liquidity more quickly, avoiding the lengthy wait times of 30 to 120 days for customer payments. Advanon operates as an authorized financial intermediary under Swiss regulations, ensuring compliance with the Anti Money Laundering Act. By facilitating flexible financing options with transparent pricing, Advanon aims to support the growth and cash flow stability of SMEs.
Flytrex
Series A in 2017
Flytrex is the largest drone-based food delivery service in the United States, primarily operating in North Carolina and Texas. The company has successfully fulfilled over 120,000 orders for various partners, including notable chains such as Little Caesars, Papa John's, and El Pollo Loco. Flytrex's service is designed to offer rapid delivery, reducing costs from $10 to $1 per package and cutting delivery times from 20 minutes to under 5. With a strong customer retention rate of 45% after two years and a household penetration of 70% within its service range, the company has garnered significant customer satisfaction, reflected in its high Net Promoter Score of 75. Flytrex employs advanced automated drone technology operated via a cloud-based control system, facilitating efficient deliveries even to hard-to-reach areas while minimizing operational expenses for retailers and delivery companies.
Altoida
Seed Round in 2016
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Inositec
Seed Round in 2016
Inositec AG, established in 2015 and based in Zurich, Switzerland, is a biotechnology company specializing in the development of novel drugs for soft tissue calcification disorders. It leverages its proprietary Inositune platform, which involves the engineering of inositol phosphate (IP6) analogs by selectively replacing phosphate groups with other chemical groups. This tunable approach enables the creation of molecules with enhanced drug-like properties, tailored for specific therapeutic indications. Inositec's lead programs focus on vascular and renal calcification disorders, including orphan indications, aiming to provide non-antibiotic, toxin-targeted therapies for conditions such as Clostridium difficile infections.
Gamaya
Series A in 2016
Gamaya is a company focused on enhancing the efficiency and sustainability of both large-scale and small-holder farming through advanced farmland mapping and diagnostics solutions. It employs patented hyperspectral imaging technology, embedded cameras, and analytical software to convert raw hyperspectral and satellite data into actionable insights for farmers. This innovative approach enables farmers to optimize their use of water, fertilizers, chemicals, and fuel, ultimately improving the quality and quantity of their agricultural production. By facilitating better decision-making, Gamaya's solutions contribute to increased crop yields while minimizing environmental impact, thereby supporting sustainable agriculture and global food security.
Amal Therapeutics
Series A in 2016
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Xeltis
Series B in 2015
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
Equippo.com
Seed Round in 2015
Equippo.com is a commercial equipment company that sells and buys used equipment for the construction industry. They bring together select manufacturers, dealers, leasing companies, and other trusted sellers of heavy equipment with buyers from all over the world, including markets like South America, Russia, and Poland. It operates an online marketplace for used construction equipment. They are very proud of their most important and unique technological innovation - the Equippo final price calculation engine makes it even easier to deal internationally: tariffs, transport, and logistics specific to your region are already included in the price displayed. Equippo.com was founded in 2014 and is headquartered in Zug, Switzerland, Equippo’s dedicated team is as international as its mission; buyers and sellers can speak with salespeople in more than nine languages.
Sequana Medical
Series C in 2015
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
CeQur Simplicity
Series C in 2015
CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.
Kuros Biosciences
Post in 2015
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.
JenaValve Technology
Series C in 2015
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
L.E.S.S.
Series A in 2015
L.E.S.S. SA, founded in 2012 and based in Renens, Switzerland, specializes in the design and development of ultra-bright and ultra-thin lighting solutions. The company offers a range of products, including inspection lighting for microscopy and workbench applications, as well as automotive lighting systems. L.E.S.S. focuses on providing high and low angle, and shadowless illumination lighting systems suitable for various sectors, including automotive, machine vision, watchmaking, micromechanics, electronics, and medical applications. The company's innovative approach aims to deliver intense and uniform lighting within a compact form factor.
UniKey Technologies
Series A in 2015
UniKey Technologies, Inc. is a company that specializes in access control solutions, offering a platform that transforms smartphones into universal electronic keys. Founded in 2010 and based in Winter Park, Florida, the company provides a smart lock system that includes touch-to-open technology, allowing users to unlock doors without removing their smartphones from pockets or purses. UniKey's platform features advanced intelligence that determines whether an authorized user is present before granting access, enhancing security and preventing unauthorized entry. The company collaborates with lock manufacturers, including Kwikset and Weiser, to develop integrated smart lock solutions like Kevo. Additionally, UniKey offers a cloud-based lock management system tailored for multifamily properties and commercial businesses, which simplifies key management and access control across various applications, including residential, hospitality, and automotive sectors.
Genkyotex
Series D in 2015
Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.
Xeltis
Series B in 2014
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
Sequana Medical
Series C in 2014
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
JenaValve Technology
Series C in 2014
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
Endosense
Series C in 2013
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Delenex Therapeutics
Series A in 2013
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Sonic Emotion
Funding Round in 2013
Sonic Emotion AG is a Swiss company specializing in innovative audio solutions that deliver immersive 3D sound experiences. Founded in 2002 and headquartered in Zurich, with research facilities in France and sales offices across Asia, Sonic Emotion offers advanced audio technologies suitable for various environments, including 3D cinemas, events, museums, and theme parks. The company's flagship product, Absolute 3D sound technology, enables natural sound reproduction using a compact system that can operate with minimal channels, making it versatile for different applications. Additionally, Sonic Emotion provides audio simulation and OEM licensing solutions, as well as Headquake, a sound enhancement application for Apple devices. The company's focus on creating engaging audio experiences positions it as a leader in the field of sound technology.
Edimer Pharmaceuticals
Series B in 2013
Edimer Pharmaceuticals focuses on developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as insufficient sweat glands, impaired temperature regulation, respiratory difficulties, and abnormal hair and tooth development. The company aims to enhance the health and quality of life for individuals affected by this orphan disease. Edimer is supported by a team of experienced biotechnology professionals and a network of esteemed clinical and scientific advisors, all committed to advancing drug development for XLHED. Through its innovative approach, Edimer seeks to provide significant and lasting improvements in the management of this condition for future generations.
JenaValve Technology
Series C in 2013
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
Windeln.de
Series C in 2013
Windeln.de, now known as Nakiki SE, is an online retailer specializing in products for babies, toddlers, children, and young mothers. The company operates in Germany, Austria, Switzerland, the Czech Republic, Spain, and China, offering a diverse range of items, including diapers, baby food, clothing, toys, strollers, child car seats, and baby monitors. Additionally, its product lineup encompasses furniture for children, dietary supplements, and cosmetics, catering not only to younger age groups but also to parents and older children. Windeln.de operates through various segments, including regional online shops and shopping clubs, focusing on providing a comprehensive selection of essential products for families.
Endosense
Series C in 2012
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Spinelab
Series C in 2012
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Pay by Shopping (deal united)
Series B in 2011
Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.
Delenex Therapeutics
Series A in 2011
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Sequana Medical
Series B in 2011
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Activaero
Series A in 2011
Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.
Delenex Therapeutics
Series A in 2010
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Nexthink
Venture Round in 2010
Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.
SmallRivers
Seed Round in 2010
SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.
JenaValve Technology
Series B in 2010
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
Pay by Shopping (deal united)
Series A in 2010
Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.
SilentSoft
Venture Round in 2010
SilentSoft, established in 2000, specializes in Machine To Machine (M2M) technology and operates as a telemetry company. The firm has developed a comprehensive range of technologies and processes designed for the effective operation of M2M networks. SilentSoft collaborates with industrial clients to deploy and manage their M2M networks, focusing on solutions for monitoring tanks and meters. By connecting these devices, the company facilitates real-time communication and data exchange, helping clients optimize operations, reduce emergency deliveries, and decrease fuel consumption and carbon emissions.
CeQur Simplicity
Series A in 2010
CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.
Activaero
Series A in 2009
Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.
Endosense
Series B in 2009
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Spinelab
Series B in 2009
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Edimer Pharmaceuticals
Series A in 2009
Edimer Pharmaceuticals focuses on developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as insufficient sweat glands, impaired temperature regulation, respiratory difficulties, and abnormal hair and tooth development. The company aims to enhance the health and quality of life for individuals affected by this orphan disease. Edimer is supported by a team of experienced biotechnology professionals and a network of esteemed clinical and scientific advisors, all committed to advancing drug development for XLHED. Through its innovative approach, Edimer seeks to provide significant and lasting improvements in the management of this condition for future generations.
ESBATech
Series B in 2008
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.
Ganymed Pharmaceuticals
Series C in 2007
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
NemeriX
Series C in 2007
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Spinelab
Series A in 2007
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Nexthink
Series A in 2007
Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.
Sequana Medical
Series A in 2007
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
ESBATech
Series B in 2006
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.
Mobileye
Private Equity Round in 2006
Mobileye is a leader in the development and deployment of advanced driver-assistance systems (ADAS) and autonomous driving technologies. The company specializes in creating a comprehensive portfolio of solutions that include both software and hardware components, designed to enhance vehicle safety and pave the way for future autonomous driving capabilities. Its offerings range from driver assistance tools to fully autonomous systems, such as Mobileye Chauffeur and Mobileye Drive. In addition to its core technologies, Mobileye provides data services aimed at optimizing maintenance operations and improving mobility infrastructure. With a strong foundation in computer vision, machine learning, mapping, and data analysis, Mobileye plays a pivotal role in shaping the future of transportation.
EndoArt
Series C in 2006
EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.
Nexthink
Seed Round in 2006
Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.
Visonys
Venture Round in 2006
Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.